BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Ikena Oncology reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Ikena Oncology announced earnings per share of $-0.48 on revenue of $4.12M. Analysts polled by Investing.com EPS of $-0.49 on revenue of $4.32M.
Ikena Oncology 's are down 57% and is trading at $2.32 , still down 86.74% from its 52 week high of $17.50 set on Monday, November 15, 2021.
Ikena Oncology shares gained 2.20% to trade at $2.32 in intra-day trade the report.
Ikena Oncology follows other major Healthcare sector earnings this month
Ikena Oncology's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar